In the pivotal clinical trial, rVIII-SingleChain met all primary endpoints. Hemophilia A is a congenital bleeding disorder characterized by deficient or defective factor VIII; nearly all affected patients
The research will focus on using Emulate’s Small Airway Lung-Chip and Intestine-Chip to enable predictive modeling of inflammatory processes in the human lung and the gastrointestinal system. The
The agreement also includes a number of additional territories outside North America, including South America and South Africa, and additional potential indications. Under the terms of the agreement,
Abivax CEO Hartmut Ehrlich said: "ABX464 is a first-in-class antiviral drug candidate for the treatment of patients with HIV-infection. It is an orally available small molecule inhibiting HIV
CCP-07 is the second product being developed for Vernalis by Tris Pharma Inc ("Tris") for the US prescription cough cold market. The first product, TuzistraXR was approved by
The consideration payable by Novartis Pharma to GSK may reach up to $1,034m and comprises a series of milestone payments as follows: $300m paid at closing $200m payable
The filter dryer, first introduced early this year, provides a completely closed system unit for isolation and drying, which minimizes operator exposure and provides a safer manufacturing environment.
Zuplenz, launched in the US in July 2015, is an anti-emetic, which does not need to be injected or swallowed, offering patients a differentiated alternative. Midatech expects that
Keith Flaherty, M.D., Director of the Termeer Center for Targeted Therapy at Massachusetts General Hospital and Associate Professor at Harvard Medical School has been named the Principal Investigator.
This approval marks the second FDA-approved indication in advanced melanoma for KEYTRUDA, which is now the first anti-PD-1 therapy approved for previously untreated advanced melanoma patients regardless of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.